Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at http://www.fivestarequities.com/ and get exclusive access to our numerous stock reports.
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) shares fell 14.30 percent to close at $22.42 a share Wednesday. The stock traded between $21.95 and $25.33 volume of 259,247 shares traded. The company has received notification from the FDA that deficiencies regarding its supplemental new drug application for feraheme injection were found that could delay the application. Shares of AMAG Pharmaceuticals have gained approximately 52.0 percent year-to-date.
Get more information on AMAG Pharmaceuticals and free access to the in-depth equity report at:
Baxter International Inc. (NYSE: BAX) shares declined 6.40 percent to close at $66.70 a share Wednesday. The stock traded between $66.31 and $69.79 on volume of 13.25 million shares traded. JPMorgan had initiated coverage on the company with a "neutral" rating.
Get more information on Baxter International and free access to the in-depth equity report at:
Clovis Oncology Inc. (NASDAQ: CLVS) shares dropped 11.60 percent to close at $64.99 a share Wednesday. The stock traded between $61.50 and $65.75 on volume of 1.18 million shares traded. According to Bloomberg, the company failed to receive any buyout offers.
Get more information on Clovis Oncology and free access to the in-depth equity report at:
Oncothyreon Inc. (NASDAQ: ONTY) shares surged 21.11 percent to close at $2.18 share Wednesday. The stock traded between $2.11 and $2.43 on volume of 14.14 million shares traded. The company announced that Merck Serono "has decided to continue clinical development of the investigational MUC1 antigen-specific cancer immunotherapy tecemotide". Shares of Oncothyreon have gained approximately 13.0 percent year-to-date.
Get more information on Oncothyreon and free access to the in-depth equity report at:
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Five Star Equities
Leave a comment...